RT Journal Article
T1 Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review.
A1 Heidegger, Isabel
A1 Kesch, Claudia
A1 Kretschmer, Alexander
A1 Tsaur, Igor
A1 Ceci, Francesco
A1 Valerio, Massimo
A1 Tilki, Derya
A1 Marra, Giancarlo
A1 Preisser, Felix
A1 Fankhauser, Christian D
A1 Zattoni, Fabio
A1 Chiu, Peter
A1 Puche-Sanz, Ignacio
A1 Olivier, Jonathan
A1 van den Bergh, Roderik C N
A1 Kasivisvanathan, Veeru
A1 Pircher, Andreas
A1 Virgolini, Irene
A1 Gandaglia, Giorgio
K1 177Lu-PSMA-617 radioligand therapy
K1 biomarkers
K1 mCRPC
AB Radioligand therapy with Lutetium-177 (177Lu)-Prostate-specific membrane antigen (PSMA) has shown to prolong survival in metastatic castration resistant prostate cancer (mCRPC). One of the major challenges for clinicians in the future is to select those patients who would benefit most from this therapy to position it in the treatment landscape of mCRPC. This, in turn, will lead to the delivery of personalized therapies. In this narrative review article we summarize recent studies investigating both predictive and prognostic clinical, imaging-based, and molecular biomarkers to predict treatment response to 177Lu-PSMA-617 radioligand therapy with the aim of identifying men who should be considered for this approach. Of note, the evidence on the role of biomarkers currently relies on small retrospective trials and their validation in larger prospective cohorts is necessary before these results can be translated in the clinical practice.
PB Sage Publications Ltd.
SN 1758-8340
YR 2022
FD 2022-02-02
LK http://hdl.handle.net/10668/20229
UL http://hdl.handle.net/10668/20229
LA en
NO Heidegger I, Kesch C, Kretschmer A, Tsaur I, Ceci F, Valerio M, et al. Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review. Ther Adv Med Oncol. 2022 Mar 5;14:10.
DS RISalud
RD Apr 7, 2025